Mean pulmonary artery pressure of 21-24 mmHg was associated with a non-significant trend toward higher all-cause mortality (37.1% vs 22.5%, p=0.063) compared to mPAP <21 mmHg over a mean 4.9-year follow-up.
Cohort (n=140)
No
Does borderline pulmonary hypertension (mPAP 21-24 mmHg) worsen all-cause mortality compared to mPAP <21 mmHg in patients with suspected pulmonary hypertension?
Patients with borderline pulmonary hypertension (mPAP 21-24 mmHg) tend to have a worse prognosis and more deteriorated hemodynamics compared to those with mPAP <21 mmHg, though mortality differences were not statistically significant.
Absolute Event Rate: 37.1% vs 22.5%
p-value: p=0.063
OBJECTIVE: Slightly elevated mean pulmonary artery pressure (mPAP) was previously termed as ''borderline pulmonary hypertension (PH)''. We examined the long-term prognosis of patients with mPAP values between 21 and 24 mmHg, who were referred with the suspicion of pulmonary hypertension. METHODS: Our retrospective study included patients with moderate-to-high echocardiographic risk who underwent right heart catheterization (RHC) between 2008 and 2021 and were followed for at least 1 year. Patients with mPAP <21 mmHg and mPAP 21-24 mmHg were compared. Demographic and clinical characteristics and prognoses of the groups were compared. All-cause mortality over a mean follow-up of 5 years (min 1-max 13 years) was evaluated. RESULTS: A total of 140 patients (mean age 53.1 ± 14.8 years, female 74.5%) with mPAP values <25 mmHg measured of the 395 diagnostic RHCs. Mean follow-up was 4.92 ± 3.13 years. NT-pro-BNP and 6-min walking distance were better in patients with mPAP <21 mmHg. Echocardiographic findings suggestive of PH were more common in mPAP 21-24 mmHg group (P < 0.05). Both the pulmonary artery wedge pressure and cardiac index values were significantly deteriorated in individuals with mPAP 21-24 mmHg (P = 0.001). All-cause mortality tended to be higher in the borderline PH group but did not reach to statistical significance. CONCLUSION: Our single-center observational study revealed that the individuals with an mPAP of 21-24 mmHg tended to have a worser prognosis than those with mPAP of <21 mmHg for up to 13-year follow-up.
Burcu Yağmur (Sun,) conducted a cohort in Suspected pulmonary hypertension (n=140). Mean pulmonary artery pressure (mPAP) 21-24 mmHg vs. mPAP <21 mmHg was evaluated on All-cause mortality (p=0.063). Mean pulmonary artery pressure of 21-24 mmHg was associated with a non-significant trend toward higher all-cause mortality (37.1% vs 22.5%, p=0.063) compared to mPAP <21 mmHg over a mean 4.9-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: